Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Change in Account Payables of $3.9 million for Q1 2026, up 246.84% year-over-year from $1.1 million in Q1 2025, and up 213.7% quarter-over-quarter from -$3.4 million in Q4 2025.
Denali Therapeutics (DNLI) Change in Account Payables (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Change in Account Payables for 10 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 246.84% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at -$1.0 million (up 45.24% YoY), while the FY2025 annual figure was -$7.5 million, down 623.31% from the prior year.
- Change in Account Payables advanced to $3.9 million in Q1 2026 per DNLI's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.8 million in Q2 2023 and bottomed at -$4.4 million in Q3 2024.
- Historically, Change in Account Payables has averaged $146882.4 across 5 years, with a median of $839000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 2098.72% — and 2023, when it soared 469.01%.
- Denali Therapeutics' Change in Account Payables stood at -$1.7 million in 2022, then decreased by 21.34% to -$2.1 million in 2023, then jumped by 161.8% to $1.3 million in 2024, then tumbled by 365.01% to -$3.4 million in 2025, then jumped by 213.7% to $3.9 million in 2026.
- Business Quant data shows DNLI's Change in Account Payables at $3.9 million in Q1 2026, -$3.4 million in Q4 2025, and -$4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 227,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 227,000.00 |
| Jun 30, 2026 | 227,000.00 |
| Mar 31, 2026 | 3.88 Mn |
| Mar 31, 2026 | 3.88 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Sep 30, 2025 | -4.07 Mn |
| Sep 30, 2025 | -4.07 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | -2.64 Mn |
| Mar 31, 2025 | -2.64 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | -4.37 Mn |
| Sep 30, 2024 | -4.37 Mn |
| Jun 30, 2024 | 3.89 Mn |
| Jun 30, 2024 | 3.89 Mn |
| Mar 31, 2024 | 635,000.00 |
| Mar 31, 2024 | 635,000.00 |